AstraZeneca Presents Tagrisso (osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today reported further evidence that Tagrisso (osimertinib), the potential new standard of care for adult patients with locally advanced o......

